



US 20210315868A1

(19) **United States**(12) **Patent Application Publication**  
**GEISSMANN et al.**(10) **Pub. No.: US 2021/0315868 A1**(43) **Pub. Date: Oct. 14, 2021**(54) **KINASE MUTATION-ASSOCIATED  
NEURODEGENERATIVE DISORDERS**(71) Applicant: **MEMORIAL SLOAN KETTERING  
CANCER CENTER**, New York, NY  
(US)(72) Inventors: **Frederic GEISSMANN**, New York,  
NY (US); **Elvira MASS**, New York,  
NY (US); **Rocio VICARIO**, New York,  
NY (US)(73) Assignee: **MEMORIAL SLOAN KETTERING  
CANCER CENTER**, New York, NY  
(US)(21) Appl. No.: **16/640,146**(22) PCT Filed: **Aug. 24, 2018**(86) PCT No.: **PCT/US2018/047964**

§ 371 (c)(1),

(2) Date: **Feb. 19, 2020****Related U.S. Application Data**(60) Provisional application No. 62/550,536, filed on Aug.  
25, 2017.**Publication Classification**(51) **Int. Cl.****A61K 31/437** (2006.01)**A61K 45/06** (2006.01)**A61P 25/28** (2006.01)(52) **U.S. Cl.**CPC ..... **A61K 31/437** (2013.01); **A61P 25/28**  
(2018.01); **A61K 45/06** (2013.01)**ABSTRACT**

The present technology relates to methods for treating, preventing, and/or ameliorating kinase mutation-associated neurodegenerative diseases, including BRAFV600E-associated neurodegenerative diseases, in a subject in need thereof. In particular aspects, the present technology relates to the use of BRAF, MEK, and/or CSF-IR inhibitors to treat, prevent, and/or ameliorate kinase mutation-associated neurodegenerative diseases, including BRAFV600E-associated neurodegenerative diseases.

